Analyst Ratings February 9, 2026

Stifel Sticks With Hold on Waters Corp After Strong Q4; Q1 Guidance Clouds Outlook

Solid fourth-quarter execution met with mixed divisional results and guidance that fell short of analyst forecasts

By Sofia Navarro WAT
Stifel Sticks With Hold on Waters Corp After Strong Q4; Q1 Guidance Clouds Outlook
WAT

Stifel has maintained its Hold rating on Waters Corporation (NYSE: WAT) after the company reported fourth-quarter results that beat expectations. The quarter showed broad-based organic growth across end markets and regions, but first-quarter guidance that came in below analyst estimates has tempered investor enthusiasm. Waters is valued at $20.15 billion and trades at a P/E of 35.18, a level described as high relative to near-term earnings growth by InvestingPro.

Key Points

  • Stifel maintained a Hold rating on Waters Corporation after the company reported fourth-quarter results that exceeded expectations.
  • Q4 outperformance was led by high single-digit growth in Pharmaceutical and Industrial end markets and positive results across all major regions.
  • First-quarter guidance issued by Waters came in below analyst expectations, drawing investor concern despite the strong Q4 showing.

Stifel has reaffirmed its Hold recommendation on Waters Corporation (NYSE: WAT) following quarterly results that outperformed consensus. The company, with a market value of $20.15 billion, is trading at a price-to-earnings ratio of 35.18, a multiple InvestingPro flags as elevated relative to near-term earnings growth.

The firm’s fourth-quarter performance delivered a beat driven primarily by high single-digit expansion in both the Pharmaceutical and Industrial end markets, accompanied by growth across all major geographic regions. These results are consistent with Waters’ reported revenue increase of 6.9% over the trailing twelve months.

Breaking the quarter down by business unit and revenue type, the Waters division recorded organic sales growth of 7%, in line with Stifel’s projection. By contrast, the TA division produced flat organic growth, missing the Street’s 2.0% projection and falling short of Stifel’s own 1.0% estimate.

Within product categories, instrument sales rose 3% on an organic basis. Recurring revenue showed stronger momentum, advancing 9% overall; service revenue climbed 8% and precision chemistries expanded 12% organically. Segment-level performance included 7% organic growth in the Pharmaceutical business, an 8% increase in Industrial, and a 3% decline in Academic & Government.

Geographically, Asia led the company’s regional performance with 11% organic growth during the quarter, while Europe and the Americas each delivered 4% organic growth.

Despite the top-line strength in the fourth quarter, Waters issued first-quarter earnings guidance that fell short of analyst expectations. That guidance update drew significant investor attention and, according to market observers, overshadowed the company’s recent outperformance versus Wall Street estimates. The lower-than-expected outlook for the upcoming quarter has heightened investor concern about the company’s near-term trajectory.

Observers note that the guidance miss underscores potential obstacles Waters may face in achieving future financial targets. Analyst expectations are central to how investors assess public companies; deviations from those expectations can materially influence sentiment and trading behavior. The company’s guidance announcement prompted a notable market reaction, reflecting how closely investors watch forward-looking statements when forming investment decisions.

In sum, Waters posted a broadly positive operational quarter with diverse revenue drivers, but the shortfall in first-quarter guidance has introduced uncertainty for near-term performance. Meanwhile, the company’s valuation multiple remains high relative to projected short-term earnings growth, a metric highlighted by InvestingPro.

Risks

  • Lower-than-expected first-quarter guidance introduces uncertainty for short-term financial performance and investor sentiment - impacts equity investors and capital markets.
  • Flat growth in the TA division relative to Street and Stifel projections suggests potential variability across business units - relevant to investors focused on product-line exposure.
  • A relatively high P/E ratio (35.18) compared with near-term earnings growth could heighten valuation risk if future earnings do not accelerate as anticipated - affects equity valuation and portfolio allocation decisions.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026